The ARID4A Knockout A-549 Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout cell population in which the ARID4A gene has been disrupted to abolish functional protein expression. This pooled format retains the inherent heterogeneity of a polyclonal population and is suited for studies that require a loss-of-function model without single-cell clonal selection. The knockout is generated using a general CRISPR/Cas9-mediated gene disruption approach, and the resulting cells are supplied as a ready-to-use tool for dissecting ARID4A-dependent regulatory networks in a cancer-relevant context.
The host A-549 cell line is a widely employed model of human lung adenocarcinoma, originally derived from alveolar basal epithelial cells. These cells exhibit an adherent, epithelial morphology and harbor an activating KRAS G12S mutation, a common driver alteration in non-small cell lung cancer. This genetic background renders A-549 cells particularly valuable for investigating the interplay between oncogenic KRAS signaling and chromatin-mediated transcriptional control. Their robust growth and well-characterized molecular landscape make them an optimal chassis for engineering knockout derivatives.
ARID4A functions as a key scaffold protein within the SIN3A?CHDAC transcriptional corepressor complex, where it facilitates histone deacetylation and epigenetic silencing of target genes. It directly interacts with SIN3A, HDAC1/2, RB1, SAP30, and SDS3 to assemble a repressive chromatin environment. ARID4A is regulated by upstream factors such as the transcription factor E2F1 and microRNA miR-31, and it transcriptionally represses critical downstream effectors including CDKN1A (p21), BAX, and PUMA. Through this network, ARID4A acts as a tumor suppressor by enforcing cell cycle arrest and promoting apoptosis; its loss disrupts this restraint and may enhance oncogenic phenotypes.
In the A-549 background, ARID4A knockout removes a key brake on KRAS-driven proliferation and survival. The absence of ARID4A-mediated repression is expected to derepress pro-proliferative and anti-apoptotic genes, thereby cooperating with the existing KRAS mutation to magnify tumorigenic traits. This polyclonal knockout model enables researchers to study how chromatin remodeling defects contribute to lung adenocarcinoma progression, epithelial-mesenchymal transition, and altered drug sensitivity. It also serves as a platform for examining compensatory transcriptional rewiring in the absence of a corepressor subunit.
This product is intended for a broad range of functional genomics applications, including mechanistic studies of chromatin remodeling and gene regulation, validation of ARID4A as a therapeutic target, and drug sensitivity screening in lung adenocarcinoma. Typical assays compatible with polyclonal knockout cells encompass western blotting for protein-level verification, RT-qPCR for transcript quantification, ChIP-qPCR to assess histone modification changes at target loci, cell proliferation and apoptosis measurements, and migration/invasion assays. The pooled nature also supports omics-scale approaches such as RNA-seq for global expression profiling. For further technical information and ordering details, please contact Ascent Research.
